Truvian raises $105M, plans to submit benchtop blood-testing tech to FDA
Benchtop blood testing startup Truvian raised $105 million in series C funding, which it plans to use to pave the way to submit its device for FDA clearance.
Shares0
Truvian Sciences plans to seek FDA clearance and CLIA certification for its benchtop blood testing device. Photo credit: Truvian Sciences
Truvian Sciences, a startup building a benchtop blood analyzer, raised $105 million in funding.
The San Diego-based company plans to use the funds to seek 510(k) clearance and a CLIA waiver from the Food and Drug Administration, with plans to make its first regulatory submission before the end of the year. The company will also look to double its 87-person team, including its recent hire of Jay Srinivasan, former vice president of automation and informatics at Abbott.